ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

February 17, 2021 17:00 ET | Source: ChemoCentryx, Inc. — Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group — — Avacopan’s effects on kidney function, patient Quality of Life,…...

Read more

VF Awards Research Grant to Pulmonary/Critical Care Medicine Physician at OSU

Lynn A. Fussner, MD, Assistant Professor at The Ohio State University (OSU), Division of Pulmonary, Critical Care, and Sleep Medicine, has been awarded a one-year grant from the Vasculitis Foundation (VF) for her study, “Role of Monocytes and Alpha-1 Antitrypsin in ANCA-Associated Vasculitis.” Dr. Fussner’s goal is to identify better…...

Read more

Pitt Scientists Identify Genetic Risks of Rare Inflammatory Disease

PITTSBURGH, Dec. 11, 2020 – In a paper published today in the American Journal of Human Genetics, a group of international collaborators led by researchers from the University of Pittsburgh School of Medicine identified new genetic associations that can predict individual susceptibility to a rare inflammatory disease called Takayasu arteritis.…...

Read more

Scientists use Clues in the Human Genome to Discover new Inflammatory Syndrome

“Our team of researchers at the NIH discovered a new form of vasculitis  and called it VEXAS. VEXAS is caused by genetic mutations in a portion  of a patient’s blood cells. Before we knew about VEXAS, these patients were diagnosed with other forms of vasculitis, such as relapsing polychondritis, polyarteritis…...

Read more

Recruiting: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week…...

Read more